ATYR
aTyr Pharma, Inc.0.7326
-0.0008-0.11%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
71.79MP/E (TTM)
-Basic EPS (TTM)
-0.83Dividend Yield
0%Recent Filings
10-K
FY2025 results
aTyr Pharma posted FY2025 net loss of $74.1M on $0.2M collaboration revenue, burning $62M in operating cash amid efzofitimod Phase 3 EFZO-FIT completion. Q4 saw topline data release showing missed primary steroid reduction endpoint (2.79mg vs 3.52mg placebo, p=0.3313), yet nominal wins in KSQ-Lung (p=0.0479), fatigue (p=0.0226), and trends to steroid-free status; efzofitimod remained well-tolerated. Cash ended at $80.9M after $66M ATM raise, funding EFZO-CONNECT Phase 2 enrollment (H1 2026 target) and FDA Type C meeting (April 2026). No capex spikes or buybacks. No annual guidance issued. Phase 3 misses risk derailing sarcoidosis approval.
8-K
Q4 2025 results; FDA meeting ahead
aTyr Pharma reported full-year 2025 net loss of $74.1M on $60.2M R&D spend, ending with $80.9M cash. Phase 3 EFZO-FIT™ missed primary endpoint in pulmonary sarcoidosis yet showed benefits in KSQ-Lung (p=0.0479) and fatigue scores. FDA meeting set for mid-April 2026. Phase 2 SSc-ILD enrollment finishes H1 2026.
8-K
Nasdaq bid price deficiency
aTyr Pharma received a Nasdaq deficiency notice on December 4, 2025, for its common stock closing below $1.00 per share over 30 consecutive business days, violating Listing Rule 5550(a)(2). The stock remains listed, with 180 days until June 2, 2026, to sustain $1.00 closes for 10 straight business days. No immediate delisting. Company will monitor prices and explore fixes like a reverse split.
10-Q
Q3 FY2025 results
aTyr Pharma posted Q3 revenue of $0.2M from Kyorin drug sales, up from zero y/y, yet ramped R&D to $22.1M (up 49% y/y) on efzofitimod manufacturing for potential BLA while wrapping EFZO-FIT. Operating loss hit $26.7M (vs $18.1M y/y), net loss $25.7M or $(0.26)/share on 97M shares, matching diluted count amid net loss position. Cash plus investments stood at $92.9M after $66.4M ATM raise, funding ops for 12+ months; op cash burn eased to $(49.8M) YTD (derived, down 11% y/y). No debt beyond leases. Cash burn funds the runway.
8-K
Phase 3 misses primary, gains QoL
aTyr Pharma reported Q3 2025 results, with Phase 3 EFZO-FIT™ missing its primary corticosteroid reduction endpoint in pulmonary sarcoidosis yet showing efzofitimod benefits in quality of life, fatigue, and steroid withdrawal at 5.0 mg/kg. Cash stood at $92.9 million. FDA meeting set for Q1 2026. Phase 2 SSc-ILD enrollment finishes H1 2026.
ATHA
Athira Pharma, Inc.
3.88+0.03
ATXS
Astria Therapeutics, Inc.
12.87-0.05
AVIR
Atea Pharmaceuticals, Inc.
3.22+0.07
CYTOF
Altamira Therapeutics Ltd.
0.07+0.00
KRRO
Korro Bio, Inc.
8.22+0.26
KYMR
Kymera Therapeutics, Inc.
84.19-1.49
LYRA
Lyra Therapeutics, Inc.
3.86-0.07
RNTX
Rein Therapeutics, Inc.
1.35-0.13
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02
TYRA
Tyra Biosciences, Inc.
22.97+0.85